Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1139 in Ulcerative Pyoderma Gangrenosum
NCT07337564Phase 2Recruiting
- Sponsor
- Shandong First Medical University
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1139 in pyoderma gangrenosum (PG), sponsored by Shandong First Medical University. Started Jan 2026; status: recruiting.
02
Drugs
SHR-1139
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT07337564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07337564.